{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:31:36Z","timestamp":1780090296434,"version":"3.54.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"DOI":"10.1038\/s41398-025-03763-z","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T04:44:49Z","timestamp":1767761089000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cytokine changes in clinical high risk for psychosis population following antipsychotic medication"],"prefix":"10.1038","volume":"16","author":[{"given":"YanYan","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiHua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiaHui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoChen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhengHui","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HaiChun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MingLiang","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HuiRu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YingYing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LingYun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChunBo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiJun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5379-7119","authenticated-orcid":false,"given":"TianHong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"3763_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-021-03569-5","volume":"21","author":"C Lin","year":"2021","unstructured":"Lin C, Chen K, Yu J, Feng W, Fu W, Yang F, et al. Relationship between TNF-alpha levels and psychiatric symptoms in first-episode drug-naive patients with schizophrenia before and after risperidone treatment and in chronic patients. BMC Psychiatry. 2021;21:561.","journal-title":"BMC Psychiatry"},{"key":"3763_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.113717","volume":"297","author":"D Chen","year":"2021","unstructured":"Chen D, Li H, Zhao Q, Song J, Lin C, Yu J. Effect of risperidone treatment on insulin-like growth factor-1 and interleukin-17 in drug naive first-episode schizophrenia. Psychiatry Res. 2021;297:113717.","journal-title":"Psychiatry Res"},{"key":"3763_CR3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jpsychires.2023.01.042","volume":"160","author":"SR Patlola","year":"2023","unstructured":"Patlola SR, Donohoe G, McKernan DP. Anti-inflammatory effects of 2nd generation antipsychotics in patients with schizophrenia: a systematic review and meta-analysis. J Psychiatr Res. 2023;160:126\u201336.","journal-title":"J Psychiatr Res"},{"key":"3763_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01688-x","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Shi H, Yang G, Yang Y, Li W, Song M, et al. Associations between expression of indoleamine 2, 3-dioxygenase enzyme and inflammatory cytokines in patients with first-episode drug-naive Schizophrenia. Transl Psychiatry. 2021;11:595.","journal-title":"Transl Psychiatry"},{"key":"3763_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/schbul\/sbab106","volume":"48","author":"JA Engh","year":"2022","unstructured":"Engh JA, Ueland T, Agartz I, Andreou D, Aukrust P, Boye B, et al. Plasma levels of the cytokines B cell-activating factor (BAFF) and a proliferation-inducing ligand (april) in schizophrenia, bipolar, and major depressive disorder: a cross sectional, multisite study. Schizophr Bull. 2022;48:37\u201346.","journal-title":"Schizophr Bull"},{"key":"3763_CR6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2215-0366(23)00025-1","volume":"10","author":"S Halstead","year":"2023","unstructured":"Halstead S, Siskind D, Amft M, Wagner E, Yakimov V, Shih-Jung Liu Z, et al. Alteration patterns of peripheral concentrations of cytokines and associated inflammatory proteins in acute and chronic stages of schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry. 2023;10:260\u201371.","journal-title":"Lancet Psychiatry"},{"key":"3763_CR7","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1177\/0004867420917449","volume":"54","author":"T Zhang","year":"2020","unstructured":"Zhang T, Xu L, Tang X, Wei Y, Hu Q, Hu Y, et al. Real-world effectiveness of antipsychotic treatment in psychosis prevention in a 3-year cohort of 517 individuals at clinical high risk from the SHARP (ShangHai At Risk for Psychosis). Aust N. Z J Psychiatry. 2020;54:696\u2013706.","journal-title":"Aust N. Z J Psychiatry"},{"key":"3763_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41537-022-00254-8","volume":"8","author":"T Zhang","year":"2022","unstructured":"Zhang T, Raballo A, Zeng J, Gan R, Wu G, Wei Y, et al. Antipsychotic prescription, assumption and conversion to psychosis: resolving missing clinical links to optimize prevention through precision. Schizophrenia. 2022;8:48.","journal-title":"Schizophrenia"},{"key":"3763_CR9","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1177\/0004867420969810","volume":"55","author":"T Zhang","year":"2021","unstructured":"Zhang T, Xu L, Wei Y, Tang X, Hu Y, Cui H, et al. When to initiate antipsychotic treatment for psychotic symptoms: At the premorbid phase or first episode of psychosis?. Aust N. Z J Psychiatry. 2021;55:314\u201323.","journal-title":"Aust N. Z J Psychiatry"},{"key":"3763_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2019.04.009","volume":"208","author":"AT Chen","year":"2019","unstructured":"Chen AT, Nasrallah HA. Neuroprotective effects of the second generation antipsychotics. Schizophr Res. 2019;208:1\u20137.","journal-title":"Schizophr Res"},{"key":"3763_CR11","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/oxfordjournals.schbul.a007040","volume":"29","author":"TJ Miller","year":"2003","unstructured":"Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29:703\u201315.","journal-title":"Schizophr Bull"},{"key":"3763_CR12","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1176\/appi.ajp.159.5.863","volume":"159","author":"TJ Miller","year":"2002","unstructured":"Miller TJ, McGlashan TH, Rosen JL, Somjee L, Markovich PJ, Stein K, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the structured interview for prodromal syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry. 2002;159:863\u20135.","journal-title":"Am J Psychiatry"},{"key":"3763_CR13","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.2147\/NDT.S85654","volume":"11","author":"T Zhang","year":"2015","unstructured":"Zhang T, Li H, Woodberry KA, Seidman LJ, Chow A, Xiao Z, et al. Interaction of social role functioning and coping in people with recent-onset attenuated psychotic symptoms: a case study of three Chinese women at clinical high risk for psychosis. Neuropsychiatr Dis Treat. 2015;11:1647\u201354.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3763_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.schres.2013.11.039","volume":"152","author":"T Zhang","year":"2014","unstructured":"Zhang T, Li H, Woodberry KA, Seidman LJ, Zheng L, Li H, et al. Prodromal psychosis detection in a counseling center population in China: an epidemiological and clinical study. Schizophr Res. 2014;152:391\u20139.","journal-title":"Schizophr Res"},{"key":"3763_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1017\/S2045796016000184","volume":"26","author":"TH Zhang","year":"2017","unstructured":"Zhang TH, Li HJ, Woodberry KA, Xu LH, Tang YY, Guo Q, et al. Two-year follow-up of a Chinese sample at clinical high risk for psychosis: timeline of symptoms, help-seeking and conversion. Epidemiol Psychiatr Sci. 2017;26:287\u201398.","journal-title":"Epidemiol Psychiatr Sci"},{"key":"3763_CR16","first-page":"571","volume":"26","author":"L Zheng","year":"2012","unstructured":"Zheng L, Wang J, Zhang T, Li H, Li C, Jiang K. The Chinese version of the SIPS\/SOPS: a pilot study of reliability and validity. Chin Ment Health J. 2012;26:571\u20136.","journal-title":"Chin Ment Health J"},{"key":"3763_CR17","unstructured":"McGlashan T, Walsh B, Woods S The Psychosis-Risk Syndrome: Handbook for Diagnosis and Follow-up. New York;Oxford University Press:2010."},{"key":"3763_CR18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00406-021-01331-2","volume":"272","author":"T Zhang","year":"2022","unstructured":"Zhang T, Wang J, Xu L, Wei Y, Tang X, Hu Y, et al. Further evidence that antipsychotic medication does not prevent long-term psychosis in higher-risk individuals. Eur Arch Psychiatry Clin Neurosci. 2022;272:591\u2013602.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"3763_CR19","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1017\/S0033291721000064","volume":"52","author":"T Zhang","year":"2021","unstructured":"Zhang T, Xu L, Li H, Cui H, Tang Y, Wei Y, et al. Individualized risk components guiding antipsychotic delivery in patients with a clinical high risk of psychosis: application of a risk calculator. Psychol Med. 2021;52:3412\u201321.","journal-title":"Psychol Med"},{"key":"3763_CR20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.schres.2012.08.030","volume":"141","author":"SZ Levine","year":"2012","unstructured":"Levine SZ, Leucht S. Early symptom response to antipsychotic medication as a marker of subsequent symptom change: an eighteen-month follow-up study of recent episode schizophrenia. Schizophr Res. 2012;141:168\u201372.","journal-title":"Schizophr Res"},{"key":"3763_CR21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1192\/bjp.bp.109.069328","volume":"196","author":"R Schennach-Wolff","year":"2010","unstructured":"Schennach-Wolff R, Seemuller FH, Mayr A, Maier W, Klingberg S, Heuser I, et al. An early improvement threshold to predict response and remission in first-episode schizophrenia. Br J Psychiatry. 2010;196:460\u20136.","journal-title":"Br J Psychiatry"},{"issue":"Suppl 1","key":"3763_CR22","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","volume":"42","author":"S Leucht","year":"2016","unstructured":"Leucht S, Samara M, Heres S, Davis JM. Dose equivalents for antipsychotic drugs: The DDD method. Schizophr Bull. 2016;42(Suppl 1):S90\u201394.","journal-title":"Schizophr Bull"},{"key":"3763_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jad.2015.03.021","volume":"180","author":"Y Hayasaka","year":"2015","unstructured":"Hayasaka Y, Purgato M, Magni LR, Ogawa Y, Takeshima N, Cipriani A, et al. Dose equivalents of antidepressants: evidence-based recommendations from randomized controlled trials. J Affect Disord. 2015;180:179\u201384.","journal-title":"J Affect Disord"},{"key":"3763_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/pcn.13476","volume":"77","author":"T Zhang","year":"2023","unstructured":"Zhang T, Wei Y, Zeng J, Ye J, Tang X, Xu L, et al. Interleukin-2\/interleukin-6 imbalance correlates with conversion to psychosis from a clinical high-risk state. Psychiatry Clin Neurosci. 2023;77:62\u20133.","journal-title":"Psychiatry Clin Neurosci"},{"key":"3763_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2022.114938","volume":"318","author":"T Zhang","year":"2022","unstructured":"Zhang T, Zeng J, Wei Y, Ye J, Tang X, Xu L, et al. Changes in inflammatory balance correlates with conversion to psychosis among individuals at clinical high-risk: a prospective cohort study. Psychiatry Res. 2022;318:114938.","journal-title":"Psychiatry Res"},{"key":"3763_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2021.136093","volume":"760","author":"A Rampino","year":"2021","unstructured":"Rampino A, Annese T, Torretta S, Tamma R, Falcone RM, Ribatti D. Involvement of vascular endothelial growth factor in schizophrenia. Neurosci Lett. 2021;760:136093.","journal-title":"Neurosci Lett"},{"key":"3763_CR27","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/mp.2015.96","volume":"21","author":"A Pillai","year":"2016","unstructured":"Pillai A, Howell KR, Ahmed AO, Weinberg D, Allen KM, Bruggemann J, et al. Association of serum VEGF levels with prefrontal cortex volume in schizophrenia. Mol Psychiatry. 2016;21:686\u201392.","journal-title":"Mol Psychiatry"},{"key":"3763_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eurpsy.2016.05.010","volume":"39","author":"R Balotsev","year":"2017","unstructured":"Balotsev R, Koido K, Vasar V, Janno S, Kriisa K, Mahlapuu R, et al. Inflammatory, cardio-metabolic and diabetic profiling of chronic schizophrenia. Eur Psychiatry. 2017;39:1\u201310.","journal-title":"Eur Psychiatry"},{"key":"3763_CR29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.neubiorev.2017.04.003","volume":"77","author":"P Katsel","year":"2017","unstructured":"Katsel P, Roussos P, Pletnikov M, Haroutunian V. Microvascular anomaly conditions in psychiatric disease. Schizophrenia - angiogenesis connection. Neurosci Biobehav Rev. 2017;77:327\u201339.","journal-title":"Neurosci Biobehav Rev"},{"key":"3763_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.lfs.2015.02.010","volume":"128","author":"R Lopes","year":"2015","unstructured":"Lopes R, Soares R, Coelho R, Figueiredo-Braga M. Angiogenesis in the pathophysiology of schizophrenia - a comprehensive review and a conceptual hypothesis. Life Sci. 2015;128:79\u201393.","journal-title":"Life Sci"},{"key":"3763_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1159\/000528770","volume":"82","author":"T Zhang","year":"2023","unstructured":"Zhang T, Zeng J, Wei Y, Ye J, Tang X, Xu L, et al. Changes in inflammatory markers in clinical high risk of developing psychosis. Neuropsychobiology. 2023;82:104\u201316.","journal-title":"Neuropsychobiology"},{"key":"3763_CR32","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2147\/NDT.S418381","volume":"19","author":"J Ye","year":"2023","unstructured":"Ye J, Wei Y, Zeng J, Gao Y, Tang X, Xu L, et al. Serum levels of tumor necrosis factor-alpha and vascular endothelial growth factor in the subtypes of clinical high risk individuals: a prospective cohort study. Neuropsychiatr Dis Treat. 2023;19:1711\u201323.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3763_CR33","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.2147\/NDT.S439097","volume":"19","author":"J Ye","year":"2023","unstructured":"Ye J, Zhang T. Serum levels of tumor necrosis factor-alpha and vascular endothelial growth factor in the subtypes of clinical high risk individuals: a prospective cohort study [response to letter]. Neuropsychiatr Dis Treat. 2023;19:2055\u20136.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3763_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1197-2","volume":"15","author":"TA Lesh","year":"2018","unstructured":"Lesh TA, Careaga M, Rose DR, McAllister AK, Van de Water J, Carter CS, et al. Cytokine alterations in first-episode schizophrenia and bipolar disorder: relationships to brain structure and symptoms. J Neuroinflammation. 2018;15:165.","journal-title":"J Neuroinflammation"},{"key":"3763_CR35","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","volume":"70","author":"BJ Miller","year":"2011","unstructured":"Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70:663\u201371.","journal-title":"Biol Psychiatry"},{"key":"3763_CR36","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bbi.2018.05.002","volume":"71","author":"D Frydecka","year":"2018","unstructured":"Frydecka D, Krzystek-Korpacka M, Lubeiro A, Stramecki F, Stanczykiewicz B, Beszlej JA, et al. Profiling inflammatory signatures of schizophrenia: a cross-sectional and meta-analysis study. Brain Behav Immun. 2018;71:28\u201336.","journal-title":"Brain Behav Immun"},{"key":"3763_CR37","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1001\/jamapsychiatry.2017.3191","volume":"74","author":"FP Hartwig","year":"2017","unstructured":"Hartwig FP, Borges MC, Horta BL, Bowden J, Davey Smith G. Inflammatory biomarkers and risk of schizophrenia: a 2-sample mendelian randomization study. JAMA Psychiatry. 2017;74:1226\u201333.","journal-title":"JAMA Psychiatry"},{"key":"3763_CR38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bbi.2012.06.010","volume":"31","author":"M Di Nicola","year":"2013","unstructured":"Di Nicola M, Cattaneo A, Hepgul N, Di Forti M, Aitchison KJ, Janiri L, et al. Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav Immun. 2013;31:90\u20135.","journal-title":"Brain Behav Immun"},{"key":"3763_CR39","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/mp.2016.3","volume":"21","author":"DR Goldsmith","year":"2016","unstructured":"Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21:1696\u2013709.","journal-title":"Mol Psychiatry"},{"key":"3763_CR40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.schres.2014.03.005","volume":"155","author":"R Upthegrove","year":"2014","unstructured":"Upthegrove R, Manzanares-Teson N, Barnes NM. Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr Res. 2014;155:101\u20138.","journal-title":"Schizophr Res"},{"key":"3763_CR41","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","volume":"63","author":"S Potvin","year":"2008","unstructured":"Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 2008;63:801\u20138.","journal-title":"Biol Psychiatry"},{"key":"3763_CR42","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3389\/fnins.2018.00296","volume":"12","author":"F Zhu","year":"2018","unstructured":"Zhu F, Zhang L, Liu F, Wu R, Guo W, Ou J, et al. Altered serum tumor necrosis factor and interleukin-1beta in first-episode drug-naive and chronic schizophrenia. Front Neurosci. 2018;12:296.","journal-title":"Front Neurosci"},{"key":"3763_CR43","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/sj.cr.7310017","volume":"16","author":"Y Shi","year":"2006","unstructured":"Shi Y, Liu CH, Roberts AI, Das J, Xu G, Ren G, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don\u2019t know. Cell Res. 2006;16:126\u201333.","journal-title":"Cell Res"},{"key":"3763_CR44","doi-asserted-by":"publisher","first-page":"21m14092","DOI":"10.4088\/JCP.21m14092","volume":"83","author":"J Zeng","year":"2022","unstructured":"Zeng J, Raballo A, Gan R, Wu G, Wei Y, Xu L, et al. Antipsychotic exposure in clinical high risk of psychosis: empirical insights from a large cohort study. J Clin Psychiatry. 2022;83:21m14092.","journal-title":"J Clin Psychiatry"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03763-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03763-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03763-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:03:15Z","timestamp":1769594595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03763-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3763"],"URL":"https:\/\/doi.org\/10.1038\/s41398-025-03763-z","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Research Ethics Committee of the Shanghai Mental Health Center granted ethical approval for the study (2017-36\u2009R). INFORMED consent was obtained from all participants during the recruitment stage. For participants under the age of 18, written parental INFORMED consent was obtained, and adolescents provided verbal assent. The research was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS APPROVAL AND CONSENT TO PARTICIPATE"}}],"article-number":"48"}}